- Home
- GHY vs STTK Comparison
GHY vs STTK Comparison
Compare GHY & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | STTK |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.5M | 459.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GHY | STTK |
|---|---|---|
| Price | $11.75 | $6.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 145.8K | ★ 502.9K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.25 | $0.71 |
| 52 Week High | $13.72 | $7.68 |
Technical Indicators
Market Signals| Indicator | GHY | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 65.29 |
| Support Level | $11.25 | $5.75 |
| Resistance Level | $12.89 | N/A |
| Average True Range (ATR) | 0.16 | 0.47 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 68.57 | 61.66 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.